ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Complement 5 Regulation Ameliorates Antibody-Mediated Rejection After Liver Transplantation in Rats

T. Tajima1, K. Hata1, J. Kusakabe1, H. Miyauchi1, X. Zhao1, S. Kageyama1, T. Okamoto1, Y. Wang2, E. Hatano1

1Dept. of HBP Surgery & Transplantation, Kyoto University, Kyoto, Japan, 2Alexion Pharmaceuticals Inc., New Haven, CT

Meeting: 2022 American Transplant Congress

Abstract number: 1212

Keywords: B cells, Efficacy, Highly-sensitized, Post-operative complications

Topic: Basic Science » Basic Science » 04 - B-cell / Antibody /Autoimmunity

Session Information

Session Name: B-cell / Antibody /Autoimmunity

Session Type: Poster Abstract

Date: Monday, June 6, 2022

Session Time: 7:00pm-8:00pm

 Presentation Time: 7:00pm-8:00pm

Location: Hynes Halls C & D

*Purpose: Antibody-mediated rejection (AMR) is a refractory rejection after donor-specific antibody (DSA)-positive or blood-type incompatible organ transplantation. Since AMR significantly deteriorates transplant outcomes, there is an urgent need to develop new therapeutic interventions for this intractable rejection.

*Methods: I. Development of a rat AMR model: Orthotopic liver transplantation (OLT) was performed from male Dark Agouti rats (DA, 240-260g) to male Lewis rats (LEW, 280-300g). In the pre-sensitized group (Group-PS), LEW were pre-sensitized by preceding skin transplantation from DA (2 x 2 cm2) 4-6 weeks prior to LT, while sham procedure was performed in non-sensitized controls (Group-NS). Tacrolimus was daily administered (0.1 mg/kg/day) up to a week or until sacrifice after LT to suppress cellular rejections.II. Evaluation of the efficacy of anti-C5 antibody (Anti-C5): Either rat Anti-C5 (20 mg/kg) or vehicle was administered intravenously on post-transplant days (PTD)-0 and -3. Blood and liver tissues were sampled on PTD-1, -3, -7, and -100 in the following 4 groups: Group-NS, -PS, -NS+Anti-C5, and -PS+Anti-C5 (n =5 each).

*Results: I. Group-PS showed increased anti-donor (DA) antibody titers (IgG: 87,100 vs 40,900, P <0.001 and IgM: 30,500 vs22,800, P<0.05) and more C4d deposition in transplanted livers than that in Group-NS (C4d-score: 1.45 vs 0.25, P<0.001) on PTD-7. Serum transaminase levels were significantly higher in Group-PS than in -NS (ALT: 447 vs 223 IU/L, P=0.01 on PTD-1). In particular, biliary damages (ALP: 237 vs 57 IU/L, P <0.001; total bile acid: 334 vs 133 nmol/mL, P<0.001; and total bilirubin: 4.0 vs 0.3 mg/dL, P<0.001) were all characteristically and significantly deteriorated on PTD-7 in Group-PS. Coagulation disorders (PT-INR, P=0.04) and thrombocytopenia (P<0.01) were also noted in Group-PS. Moreover, histopathological grading was significantly deteriorated by skin pre-sensitization (C4d+h-score: 1.9 vs 0.4, P<0.001 on PTD-3 and 4.4 vs 1.2, P<0.001 on PTD-7). Collectively, Group-PS satisfied all the Banff criteria for AMR diagnosis.II. Intrahepatic biliary damages were significantly ameliorated by anti-C5 administration (Group-PS vs Group-PS+Anti-C5 on PTD-7, bilirubin: 4.0 vs 0.7, P<0.001 [Fig.1]; TBA: 334 vs 200, P=0.01; ALP: 237 vs 88, P<0.001), followed by improved PT-INR (P=0.04 on PTD-7). Histopathological evaluation demonstrated significant protection by anti-C5 administration (h-score on PTD-1, -3, and -7: 0.7 vs 0.0, P<0.001; 1.9 vs 0.15, P<0.001; and 3.0 vs 0.5, P<0.001, respectively).

*Conclusions: We developed a rat model of LT-AMR that meets all the diagnostic criteria for AMR, and demonstrated the efficacy of C5-targeted inhibition for this refractory rejection.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

To cite this abstract in AMA style:

Tajima T, Hata K, Kusakabe J, Miyauchi H, Zhao X, Kageyama S, Okamoto T, Wang Y, Hatano E. Complement 5 Regulation Ameliorates Antibody-Mediated Rejection After Liver Transplantation in Rats [abstract]. Am J Transplant. 2022; 22 (suppl 3). https://atcmeetingabstracts.com/abstract/complement-5-regulation-ameliorates-antibody-mediated-rejection-after-liver-transplantation-in-rats/. Accessed May 30, 2025.

« Back to 2022 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences